years it has been known that thrombocytopenia, leukopenia, and hypercoagulability of blood occur in many species after the administration of bacterial endotoxins (1) . The pathophysiologic basis for the thrombocytopenia has been a matter of controversy. Experiments in vitro have demonstrated a requirement for divalent cations and heat labile serum factors for endotoxin-mediated platelet damage (2, 3) . Other findings have suggested that complement is not involved: the metal requirements for the endotoxin effects in vitro are not those which have been shown to maximize complement-fixation reactions or complement-mediated cytotoxic reactions, and no consumption of whole complement has been demonstrated in the in vitro reaction (4) . Nevertheless, the resemblance between the thrombocytopenia induced in vivo and the complement-mediated immune adherence reaction has been noted by several authors (5, 6) . Development of the hypercoagulable state has been thought to be a consequence of platelet damage (7) .
In this report the role of complement in these reactions has been evaluated with particular reference to the contribution of the two recently described pathways of complement activation. The classical complement pathway
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The Journal of Clinical Investigation Volume 52 February 1973 proceeds through activation of the early complement components, Cl, C4, and C2, to activation and cleavage of C3 and the complement proteins which act later in the sequence. The alternate or properdin pathway acts through another series of proteins to enter the complement sequence at the C3 step (8) (9) (10) (11) . In defining the role of these two pathways, this study utilized the recently described strain of guinea pigs with a genetically controlled deficiency in C4 (C4D)' (12) . These animals have an intact alternate pathway but absence of function of the classical pathway due to the deficiency in C4. Bacterial endotoxins are known to be potent activators of the alternate pathway (13, 14) and their effects are thought to be mediated by the classical pathway only in rare circumstances (15) . By studying the biological consequences of endotoxin administration in C4D animals it has been possible to establish the importance of the classical complement pathway in mediating these phenomena. By extending these studies to cobra venom factor (CVF)-treated normal animals it has also been possible to show that activation of the late complement components is required.
METHODS
Endotoxin lipopolysaccharide (LPS). The LPS used for all the experiments was a phenol-water extract of Escherichia coli. (0127:B8) obtained from Difco Laboratories (lot 562875), Detroit, Mich. The mean lethal dose (LD50) of the E. coli endotoxin for NIH multipurpose guinea pigs was 1.0 mg/kg and this dose of endotoxin was administered in all studies reported here.
Experimental animals. "NIH multipurpose" guinea pigs, the strain from which the C4D guinea pigs were derived, were obtained from the NIH animal production section, and used as the normal guinea pigs. C4D guinea pigs were also obtained from the NIH animal production service, and screened by a hemolytic assay for the presence or absence of C4. Sera from 20 representative C4D and NIH animals were examined for anti-endotoxin antibody by a flocculation test utilizing E. coli-LPS-coated bentonite particles (16) . Utilizing this technique, no antibody could be detected at the lowest serum dilution tested (1/3).
Preparation of C3-9-depleted animals with CVF. Vials of 500 U lyophilized purified CVIF (lots 40021 and 10012) were obtained from Cordis Corp., Miami, Fla., and stored at -200C. Just before use, the lyophilized material was dissolved in 5 ml ice-cold distilled water. Injections into NIH multipurpose guinea pigs were by the intraperitoneal route in doses of 20 U/100 g animal weight. Experiments performed on CVF-treated guinea pigs were always done 20 h after injection, and C3-9 levels were determined on all animals before use. With this dose of CVF, titers of the C3-9 complex were less than 1% of normal.
Preparation of complement reagents and methods for titrations. Preparation of veronal-buffered saline (VBS), dextrose veronal-buffered saline (DVBS) containing gelatin, Ca++ and Mg++, VBS with added 0.01 M ethylenediaminetetraacetic acid (EDTA buffer), sources of antibody, prepa-'Abbreviations used in this paper: C4D, C4 deficient; CVF, cobra venom factor. ration of optimally sensitized sheep erythrocytes (EA) and of complement cell intermediates, and the method of C3-9 complex titrations have all been described previously (17, 18) . Pooled Wlhite blood cell and platelet determiniations. WVhite blood cell (WBC) and platelet counts were made on 1 ml EDTA anticoagulated retro-orbital blood samples using an electronic particle counter (Coulter Electronics, Inc., Hialeah, Fla.) and standard techniques (19, 20) . 100 cell differential leukocyte counts were done on air-dried, Wright's stained smears.
Clotting time. Cardiac punctures were performed with a 19 gauge small vein infusion set (Abbott Laboratories, North Chicago, Ill.). To avoid contamination with tissue fluids, blood for clotting studies was used only when the needle was placed directly into the cardiac chambers without manipulation and blood flow was immediate, rapid, and uninterrupted. 1 ml of blood was withdrawn with a 6 ml disposable polypropylene syringe and discarded. A fresh polypropylene syringe was then attached to the infusion set, and an additional 4 ml was withdrawn. 1-ml portions were placed into each of two 13 X 100-ml glass tubes and each of two 13 X 100-mm siliconized glass tubes at 250C. A stop watch was started when blood was placed in the first tube. The first glass tube was gently tilted 450 at 1-mim intervals until it could be inverted 1800 without blood flowing. The tube was then gently tapped to find if the clot was solid, and formation of a solid clot was taken as the end point. The same procedure was repeated sequentially with tubes number 2, 3, and 4. The clotting times of the second and fourth tubes were recorded as the glass and silicon times respectively.
RESULTS
Effect of endotoxin on C4 and C3-9 levels in normal and C4D guinea pigs. Blood samples of 1.0 ml for C4 and C3-9 were obtained from the retro-orbital sinus of 10 normal and 10 C4D guinea pigs, just before (T.) and at 15 min after the intravenous injection of E. coli endotoxin. Groups of 10 normal and 10 C4D guinea pigs were bled at T. and 15 min to obtain control values. All blood samples were allowed to clot at room tempera-ture for 60 min, and were then centrifuged at 3,000 rpm for 5 min. The supernates were decanted and titrated for C4 and C3-9. The complement titers at 15 min were expressed as a percent of the To complement levels for each individual animal, and the mean of each experimental group determined.
Complement levels of samples obtained 15 min after the injection of endotoxin into normal guinea pigs revealed a mean decrease of 12%±2 SE in C4 and 29%-*-4 in C3-9 (Table I ). In the C4D guinea pigs a 16%±3 decrease in the C3-9 complex was observed. Consumption of C3-9 in C4D animals with complement activation limited to the alternate pathway was significantly less P < 0.02) than that observed in the normal animals with both a functional alternate and classical complement pathway. No significant decrease in C4 or C3-9 was noted in the nonendotoxin-treated control groups.
Effect of endotoxin on platelets and WBC in normal and C4D guinea pigs. Base-line (T.) WBC and platelet counts were determined on retro-orbital blood samples from eight normal and eight C4D guinea pigs. Each animal was then injected i.v. with E. Coli endotoxin, and retro-orbital blood samples for platelet and WBC counts taken at intervals of 15 min, 2 h, and in some cases either 4 or 24 h after injection of the endotoxin. Differential WBC counts were performed at the 15 min interval on two animals from each group. A control group of eight normal and eight C4D guinea pigs were given 0.1 ml/100 g body weight sterile saline instead of endotoxin, and bled at similar time intervals for platelet and WBC counts. The change in platelet and WBC counts was expressed as a percent of the initial (T.) count for each animal, and a mean calculated for each experimental group. No differences in the initial platelet and WBC counts were noted between the normal and C4D animals; mean platelet counts were 744,000-+SD 103,000 and 760,000+-SD 201,000 respectively, mean WBC counts were 9,000+SD 2870 and 9,300+SD 1650. (8) , saline-treated C4D animals 106±11.6% (8) , CVFtreated normals given endotoxin 95±5% (5).
The injection of endotoxin into normal guinea pigs resulted in a decrease in platelets to 5+1% SE at 15 min with a partial return (59.7±14%) to normal levels by 2 h (Fig. 1) . In those animals which survived the injection of endotoxin (5/8), platelet counts returned to normal by 24 h. When the same dose of endotoxin was injected into C4D guinea pigs there was no decrease in platelet counts.
The development of leukopenia after the injection of endotoxin was observed in both animal groups (Fig. 2) . Differential WBC counts at the 15 min interval revealed neutropenia in both the normal and C4D animals.
Effect of endotoxin on platelets and WBC in CVFtreated guinea pigs. Five NIH multipurpose guinea pigs were given CVF as described above. 20 h after the injection of CVF, base-line platelet and WBC counts were performed. Base-line platelet counts were not different (mean count 760,0001SD 74,000) from the normal and C4D animals, but a mild leukocytosis was observed (mean WBC count 10,800±SD 2000). The animals were then given endotoxin and platelet, and WBC counts determined at 15 min, 2, and 4 h.
As can be seen in Fig. 1 treatment of normal guinea pigs with CVF prevented the profound fall in platelets seen in normal animals after the injection of endotoxin. The leukopenia (Fig. 2) was, however, unmodified.
Effect of endotoxin and platelets in C4D guinea pigs with reconstituted C4 levels. Three C4D guinea pigs were injected i.v. with 4 ml of pooled normal guinea pig serum resulting in a restoration of functional C4 activity as measured by hemolytic assay (C4 titers were in the range of 10,000-12,000). 30 min after the administration of C4, blood samples for base-line platelets were obtained. The animals were then injected with endotoxin i.v. and serial blood specimens obtained for platelet counts. Controls consisted of C4D guinea pigs with restored C4 levels given saline, and normal guinea pigs given endotoxin.
The results graphed in Fig. 3 toxin-treated normal animals 52±-8% (8) , endotoxin-treated C4D animals 41±-3% (8) , saline-treated normal animals 139±-6% (8) , saline-treated C4D animals 135+30%o, (8) CVF-treated normal animals given endotoxin 25±1%o (5) . Normal Effect of endotoxin on the clotting time in C4D guinea pigs with reconstituted C4 levels. 4 ml of pooled normal guinea pig serum (C4 titer 80,000) was injected i.v. into each of 12 C4D guinea pigs. Clotting times were determined on six animals 15 min after the administration of normal guinea pig serum. The second group of six animals was given endotoxin 15 min after receiving normal serum, and clotting times performed 15 min later. Reconstitution of C4 levels in C4D guinea pigs resulted in a significant (P < 0.001 when compared with C4D guinea pig controls) acceleration of 
The number of animals are indicated in parentheses. * Expressed as the mean+SE; C4D, animals deficient in C4; CVF, cobra venom factor.
I See text.
clotting when the animals were given endotoxin (Table  11) . A mean silicon clotting time of 34.1 min ±2.2 was obtained in the reconstituted animals not given endotoxin, while the reconstituted animals given endotoxin had a mean silicon clotting time of 22.7 min +0.7. DISCUSSION In this study the in vivo effects of bacterial endotoxins on the development of thrombocytopenia, leukopenia, and the hypercoagulable state have been examined. The role of the two major known complement pathways in production of these effects has been explored. These studies were made possible by the availability of guinea pigs with a genetically controlled inability to synthesize C4, one of the early components in the classical complement pathway (12) . Incubation of the sera of these animals with endotoxin leads to consumption of the late components of complement (8) . Since the C4D ani-' mals have a complete block in function of the classical complement pathway, these studies (8) ternate complement pathway and produces its biological effects by this means.
When endotoxin is injected into C4D guinea pigs, no precipitous fall in platelet count is observed, although normal animals sustain a 95% decrease in platelet levels. Platelet levels are not lowered even though the alternate complement pathway is activated in C4D aniinals as evidenced by the fall in the serum level of C3-9. If the level of circulating C4 is restored in C4D animnals, the expected decrease in platelet count is observed.
These results demonstrate that the thrombocytopenia observed in guinea pigs on injection of endotoxin is indeed complement related and, moreover, despite the fact that endotoxin is a potent activator of the alternate pathway, that the classical pathway is requisite for the production of thrombocytopenia. In these studies, there was a clear dissociation between the effects of endotoxin on platelets in C4D animals and the effect of endotoxin on circulating granulocytes. Leukopenia was seen in all animal groups and did not appear to be complement related.
When endotoxin is administered to CVF-treated normal guinea pigs, a similar failure to develop thrombocytopenia, but not leukopenia, is observed. CVF has been shown to deplete guinea pigs of the late components of complement but does not affect levels of the early components C1, C4, and C2 (22) . The data suggest that thrombocytopenia is a consequence of activation of the late complement components, but that activation of these components must proceed through activation of the classical pathway. Activation of the alternate pathway does not produce this effect.
The second part of this study examined the role of (5, 6) . This possibilitv has been directly tested using C4D or normal guinea pig serum, endotoxin, and C4D or normal guinea pig platelets as the target cell. In these studies immune adherence reactivity was generated by both pathways (25) A second possible explanation for these findings is provided by our observation that the alternate pathway is not directly activated by antibodies directed at antigens localized on intact mammalian membranes and thus does not damage the membrane of antibody-sensitized cells (26, 27) . A portion of injected endotoxin is known to attach to formed elements in the blood. In the rabbit, evidence has been presented that circulating platelets become rapidly coated with injected endotoxin (28) . Perhaps this portion of the injected endotoxin is responsible for the coagulopathy. The endotoxin which is not cell bound may activate the alternate pathway but does not produce platelet damage. Although C4D and normal guinea pigs utilized in this study did not have antibody detectable by the bentonite flocculation test, they undoubtedly had low levels of "natural" antibodies to endotoxins (29) . Presumably, in normal animals, these antibodies, interacting with miembrane-bound enlotox in, activated the classical complement sequence and produced thrombocytopenia, either through an immune adherence mechanism (5, 6) or by direct damage to the platelet membrane. Because anti-membrane antibodies did not activate the alternate complement pathway, C3 and the late components of complement were not fixed to the endotoxin-coated membrane in the C4D animals and platelets were neither sequestered nor destroyed.
One may attempt to relate these findings to those obtained in human diseases, however, it should be stressed that there are marked differences in the biological reactivity of various species to LPS. In clinical gramnegative bacteremia, a state considered by some to be analogous to endotoxemia in animals, hypercoagulabilitN, and mild thronmbocytopenia are not infrequently seen (30) . These latter findings may be related to activation of complement, and on the basis of the data presented here the distinct possibility exists that only one of the two complement pathways is involved in the production of these phenomena. If such is the case, selective manipulation of the complement system in endotoxemlia may be of some clinical importance.
